miR-486 improves fibrotic activity in myocardial infarction by targeting SRSF3/p21-Mediated cardiac myofibroblast senescence

J Cell Mol Med. 2022 Oct;26(20):5135-5149. doi: 10.1111/jcmm.17539. Epub 2022 Sep 18.

Abstract

The regulation of fibrotic activities is key to improving pathological remodelling post-myocardial infarction (MI). Currently, in the clinic, safe and curative therapies for cardiac fibrosis and improvement of the pathological fibrotic environment, scar formation and pathological remodelling post-MI are lacking. Previous studies have shown that miR-486 is involved in the regulation of fibrosis. However, it is still unclear how miR-486 functions in post-MI regeneration. Here, we first demonstrated that miR-486 targeting SRSF3/p21 mediates the senescence of cardiac myofibroblasts to improve their fibrotic activity, which benefits the regeneration of MI by limiting scar size and post-MI remodelling. miR-486-targeted silencing has high potential as a novel target to improve fibrotic activity, cardiac fibrosis and pathological remodelling.

Keywords: SRSF3; fibrosis; miR-486; regeneration of myocardial infarction; senescence of cardiac myofibroblasts.

MeSH terms

  • Cicatrix / pathology
  • Fibrosis
  • Humans
  • MicroRNAs* / genetics
  • Myocardial Infarction* / genetics
  • Myocardial Infarction* / pathology
  • Myocardial Infarction* / therapy
  • Myocardium / pathology
  • Myofibroblasts / pathology
  • Serine-Arginine Splicing Factors / genetics

Substances

  • MIRN486 microRNA, human
  • MicroRNAs
  • SRSF3 protein, human
  • Serine-Arginine Splicing Factors